Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial

References

• Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299–304.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al.; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903–13.
   PubMed Web of Science ®Google Scholar
• Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–814.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.
   PubMed Web of Science ®Google Scholar
• Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–19.
   PubMed Web of Science ®Google Scholar
• Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv. 2007;69:1064–74.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al.; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344–51.
   PubMed Web of Science ®Google Scholar
• Mosseri M, Miller H, Tamari I, Plich M, Hasin Y, Brizines M, et al. The titanium-NO stent: results of a multicenter registry. EuroIntervention. 2006;2:192–6.
   PubMedGoogle Scholar
• Karjalainen PP, Ylitalo A, Airaksinen KEJ, Nammas W. Five-year clinical outcome of titanium nitride-oxide-coated bioactive stent implantation in a real world population: a comparison with paclitaxel-eluting stents: The PORI registry. J Interv Cardiol. 2011;24:1–8.
   PubMed Web of Science ®Google Scholar
• Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, et al. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. Int J Cardiol.2012 Dec 3 [Epub ahead of print].
   Google Scholar
• Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, et al. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus- eluting stents in acute coronary syndrome: the BASE-ACS trial. EuroIntervention. 2012;8:306–15.
   PubMed Web of Science ®Google Scholar
• Buehl A, Zoefel P. SPSS 11: Introduction in modern data analysis, 8th ed. Munich, Germany: Addison-Wesley; 2002.
   Google Scholar
• Silber S, Windecker S, Vranckx P, Serruys PW; RESOLUTE All Comers Investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011; 377:1241–7.
   PubMed Web of Science ®Google Scholar
• Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).J Am Coll Cardiol. 2011; 58:11–18.
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, et al.; SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58:19–25.
   PubMed Web of Science ®Google Scholar
• Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, et al. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. JACC Cardiovasc Interv. 2011;4:1104–15.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietilä M, et al. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. Ann Med. 2009;21:1–9.
   Google Scholar
• Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.
   PubMed Web of Science ®Google Scholar
• Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovasc Interv. 2009;2:504–12.
   PubMed Web of Science ®Google Scholar